Profil
Dr. Mikel P.
Moyer is Vice President-Molecular Discovery at Raze Therapeutics, Inc.
Dr. Moyer was previously employed as Chief Scientific Officer by Loxo Oncology, Inc., Vice President-Molecular Discovery by Epizyme, Inc., Medicinal Chemist by Abbott Laboratories, a Principal by Pfizer Inc., and Director-Medicinal Chemistry by The Broad Institute, Inc.
He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Berkeley.
Anciens postes connus de Mikel P. Moyer
| Sociétés | Poste | Fin |
|---|---|---|
| LOXO ONCOLOGY INC | Directeur Technique/Scientifique/R&D | 28/10/2014 |
| EPIZYME, INC. | Corporate Officer/Principal | 01/04/2014 |
Raze Therapeutics, Inc.
 Raze Therapeutics, Inc. BiotechnologyHealth Technology Raze Therapeutics, Inc. engages in the discovery and development of oncology therapeutics. It offers a pipeline of one-carbon (1C) metabolism therapeutics across solid and hematologic cancers, including genetically-defined cancers. The company was founded by Vamsi Mootha, Joshua Rabinowitz, David Sabatini, and Adam Friedman on August 8, 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formation de Mikel P. Moyer
| University of Michigan | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| Entreprise privées | 4 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
Raze Therapeutics, Inc.
Raze Therapeutics, Inc. BiotechnologyHealth Technology Raze Therapeutics, Inc. engages in the discovery and development of oncology therapeutics. It offers a pipeline of one-carbon (1C) metabolism therapeutics across solid and hematologic cancers, including genetically-defined cancers. The company was founded by Vamsi Mootha, Joshua Rabinowitz, David Sabatini, and Adam Friedman on August 8, 2014 and is headquartered in Cambridge, MA. | Health Technology |